Challenges in the treatment of hepatitis C in children.
Hepatitis C infection in children is associated with a unique set of challenges for clinicians and investigators. Although the prevalence of HCV infection is lower in children than in adults, it is important to identify infected children to monitor progression of liver disease and to make appropriate interventions to minimize factors that may exacerbate progression. Identification requires understanding of risk factors important in children, primarily exposure at or near the time of birth. The natural history of this infection in most children is either more benign or significantly prolonged than that of infection acquired in adulthood. Reasons for this difference in natural history must be explored and possibly even exploited in the care of adult patients with HCV infection. Identification of appropriate pediatric candidates for treatment and definition of optimal therapy for these children require ongoing study. Lastly, as perinatal transmission becomes the primary mode of acquisition for new pediatric infections, factors that increase or decrease the likelihood of this transmission must be identified, and effective preventive interventions must be put into practice. There are important differences in the clinical features, natural history, and response to therapy between pediatric and adult patients with HCV infection. Understanding of these differences will allow optimal care for affected children and perhaps better understanding of the pathophysiology and pure natural history of this disease.
Jonas
M M
MM
Department of Pediatrics, Harvard Medical School, and Children's Hospital, Boston, Massachusetts, USA. maureen.jonas@tch.harvard.edu
D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D005260:Female; D006526:Hepatitis C / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical; D007372:Interferons / Q000008:administration & dosage / Q000627:therapeutic use; D011247:Pregnancy; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D014481:United States / Q000453:epidemiology
D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons